StockData

Cardlytics vs RUM

CDLX and RUM side by side, both in computer programming, data processing, and other computer related services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CDLX and RUM compare

RUM is the larger company, worth 304 times as much as Cardlytics ($3.0B against $9.7M).

RUM grew revenue faster over the last twelve months (82.6% versus −25.3% for Cardlytics).

Cardlytics keeps more of each dollar of sales as profit, with a net margin of −20.8% compared with −117% at RUM.

RUM scores higher on the StockData Score (8 against 7 for Cardlytics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCDLXRUM
Size and price
Market cap$9.7M$3.0B
Share price$1.65$5.96
Change, 1 year−88.5%−9.1%
Change, 5 years−99.8%−38.9%
Beta (5Y)2.501.37
Employees275156
StockData Score
Total score78 (better)
Valuation score1 (better)0
Growth score02 (better)
Performance score11
Health score55
Dividend score00
Valuation
P/S0.1× (better)15.6×
FCF yield−74.1%−7.5% (better)
Growth
Revenue growth (TTM)−25.3%82.6% (better)
Revenue growth, 5Y average4.5%–
Profitability
Operating margin−19.2% (better)−121%
Net margin−20.8% (better)−117%
FCF margin−4.1% (better)−117%
Return on equity–−73.5%
Return on invested capital–−560%
Financial health
Current ratio1.822.05 (better)
Altman Z-score−8.241.99 (better)
Piotroski F-score66
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions29.6%14.3%
Insider net buying, 12 months−$406K$4.2M (better)

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.